Patients with advanced Hodgkin lymphoma treated with BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) did not show a progression-free survival (PFS) when compared with patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), according to a study published in the Journal of Clinical Oncology.1
Investigators conducted a post-hoc analysis of the HD2000 trial, which compared 6 cycles of ABVD, 4 escalated plus 2 standard cycles of BEACOPP, and 6 cycles of COPP-EBV-CAD (cyclophosphamide, lomustine, vindesine, melphalan, prednisone, epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanced stage Hodgkin lymphoma.
The study included 295 evaluable patients. After a median follow-up of 10 years, results showed that the 10-year PFS was highest in the CEC arm (76%), followed by BEACOPP (75%), and ABVD arm (69%). Overall survival results were 86%, 84%, and 85%, respectively.
Out of the 13 second malignancies reported, 1 occurred in the ABVD arm and 6 occurred in each the BEACOPP and CEC arms.
The authors concluded that although patients treated with ABVD, BEACOPP, or CEC had similar overall survival results, longer follow-up did not show a PFS advantage with BEACOPP when compared with ABVD. These results were attributed to higher mortality rates due to second malignancies after treatment with BEACOPP and CEC.
- Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi [published online ahead of print on December 28, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.62.4817.